Pharmerica (PMC) Tops Q3 EPS by 5c; Boosts FY14 Outlook

Pharmerica (NYSE: PMC) reported Q3 EPS of $0.45, $0.05 better than the analyst estimate of $0.40. Revenue for the quarter came in at $470.2 million versus the consensus estimate of $439.63 million.

Pharmerica sees FY2014 EPS of $1.62-$1.64, versus prior guidance of $1.58-$1.62 and the consensus of $1.59. Pharmerica sees FY2014 revenue of $1.850-1.875 billion, versus prior guidance of $1.760-1.8000 billion and the consensus of $1.79 billion.

For earnings history and earnings-related data on Pharmerica (PMC) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Bernstein SocGen Group Reiterates Outperform Rating on JD.com, Inc (JD), 'very cheaply valued'
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c